FDA Approves Rhapsido® (Remibrutinib), the First Targeted Therapy for Symptomatic Dermographism
Symptomatic dermographism (SD) is a form of physical urticaria in which minor mechanical force, such as light scratching, friction from clothing, or stroking of the skin, induces localized erythema, pruritus, and wheal formation (1).
SD is the most common subtype of chronic inducible urticaria (CIndU) seen in clinical dermatology and allergy practice. Together with chronic spontaneous urticaria (CSU), SD accounts for more than 90% of all chronic urticaria cases in adult populations (1).
The condition inflicts a substantial human burden on affected patients, as routine daily physical activities and minimal skin contact can provoke uncomfortable hives, burning sensations, and intense pruritus (1).
Unmet Needs in Clinical Management
For decades, up-dosed second-generation H1 antihistamines have remained the cornerstone of treatment for physical urticarias. However, symptom control remains suboptimal for many patients, with more than half of those with symptomatic dermographism continuing to experience persistent symptoms and unpredictable flare-ups despite optimized antihistamine therapy. As a result, clinicians have long faced a significant treatment gap, lacking a targeted oral therapy specifically designed to address the underlying disease mechanisms driving refractory symptomatic dermographism (1).
FDA Approves Remibrutinib for adult patients with SD
The U.S. Food and Drug Administration (FDA) has approved Rhapsido (remibrutinib), an oral, highly selective Bruton's tyrosine kinase (BTK) inhibitor, marking it as the first and only FDA-approved prescription medication specifically indicated for adult patients with symptomatic dermographism (SD) whose symptoms remain inadequately controlled by standard H1 antihistamines (1).
Rhapsido® (remibrutinib) is a novel, highly potent oral Bruton's tyrosine kinase (BTK) inhibitor designed for high selectivity. By targeting the intracellular BTK signaling pathway, remibrutinib suppresses the activation of mast cells and basophils, key drivers of chronic urticaria. This targeted mechanism disrupts the downstream inflammatory cascade, reducing histamine release and helping prevent the wheal formation, pruritus, and inflammation that characterize symptomatic dermographism (1).
Rhapsido was previously approved for adult CSU refractory to H1 antihistamines; this expansion establishes Rhapsido as the only prescription monotherapy approved across the two most prevalent forms of chronic hives (1).
Clinical Evidence & Landmark Phase III Trial
The FDA approval was supported by results from the Phase III RemIND trial (ClinicalTrials.gov identifier: NCT05976243), a 52-week, randomized, double-blind, placebo-controlled basket study evaluating oral remibrutinib in adults with physical urticarias who remained symptomatic despite treatment with H1 antihistamines (1,2).
In the symptomatic dermographism cohort, the primary efficacy endpoint was the proportion of patients achieving complete resolution of hives, defined as a Total Fric Score (TFS) of 0 following standardized mechanical skin provocation testing (1,2).
Key Clinical Findings
Superior complete response rates at Week 12: By Week 12, 29.3% of patients treated with Rhapsido® achieved complete hive resolution, compared with 14.0% of those receiving placebo (p = 0.0229) (1).
Rapid onset of symptom relief: Clinically meaningful and statistically significant improvements in disease activity were observed as early as Week 2, demonstrating a rapid onset of action with continuous treatment (1,2).
These findings highlight the potential of remibrutinib to provide both early symptom control and sustained clinical benefit in patients with symptomatic dermographism inadequately controlled with antihistamine therapy (1,2).
Safety & Precautions
Safety Profile: Across clinical studies up to 24 weeks, Rhapsido demonstrated a favourable and predictable safety profile in SD consistent with observations in CSU clinical trials (1).
Common Adverse Events: The most frequently reported treatment-emergent adverse reactions (incidence ≥3%) included nasopharyngitis (nasal congestion, sore throat, runny nose), bleeding, headache, nausea, and abdominal pain (1).
Clinical Monitoring: Clinical trial data showed that treatment with Rhapsido does not require routine baseline or ongoing laboratory safety monitoring (1).
Conclusion
The FDA approval of Rhapsido represents a paradigm shift for allergy and dermatology specialists treating refractory symptomatic dermographism, providing a proven oral targeted agent for patients failing standard antihistamines.
Beyond SD and CSU, remibrutinib is undergoing active Phase III clinical evaluation for other immune-mediated inflammatory diseases, including hidradenitis suppurativa (HS), food allergies, and relapsing multiple sclerosis (RMS) (1).
About the Author
Dr. Manisha Dadlani is a Dental Surgeon and Medical Writer with 5+ years of clinical experience and formal training in medical writing. She combines clinical expertise with analytical thinking to develop evidence-based, insight-driven content that supports effective scientific communication across the healthcare and life sciences landscape.
References:
Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU). October 7, 2026. https://www.novartis.com/news/media-releases/novartis-rhapsido-remibrutinib-receives-fda-approval-first-treatment-symptomatic-dermographism-sd-expanding-its-use-beyond-chronic-spontaneous-urticaria-csu
Landmark Trial Registry (NCT05976243): A 52-week Multi-centre, Randomized, Double-blind, Placebo-Controlled, Basket Study with an Open-label Extension to Investigate the Efficacy, Safety, and Tolerability of Remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in Adults Inadequately Controlled by H1-antihistamines (RemIND). ClinicalTrials.gov, National Library of Medicine (NLM), ID: NCT05976243. https://clinicaltrials.gov/study/NCT05976243
Disclaimer
The content published on this platform has been developed by independent medical writers from diverse healthcare backgrounds, including members of the MedWriters Alumni Network. While every effort has been made to ensure accuracy, the authors, Rxnews team, partners, agents, and sponsors accept no responsibility for errors, omissions, or inaccuracies in this article, whether due to negligence or otherwise, nor for any consequences arising from its use. Inclusion or exclusion of any product does not imply endorsement or rejection by the publisher. For complaints or feedback, please write to contact@rxnews.in
Comments